Literature DB >> 18203045

Clozapine in China.

Y-L Tang1, P-X Mao, F Jiang, Q Chen, C-Y Wang, Z-J Cai, P B Mitchell.   

Abstract

Clozapine remains one of the most commonly used antipsychotic medications in China. As China has the largest population internationally on clozapine treatment, its experience and research findings are of keen interest to Western psychiatrists. However, most of the related papers have hitherto been published only in Chinese language journals. Here we review mainly Chinese-language publications on the use of clozapine in China. A descriptive study based on literature identified from searches of Medline and the China National Knowledge Infrastructure (CNKI) databases (1979-2007), and other hand-picked references. Unlike the situation in other countries, clozapine is still widely used for a number of psychiatric disorders in China, though the prescription of other second-generation antipsychotics (SGAs) is also increasing. About 25-60% of all treated patients with schizophrenia receive clozapine; and clozapine is preferred by some as a first-line treatment for schizophrenia. Clozapine is also used for other conditions such as mania, treatment-resistant depression and drug abuse. The average daily dose is between 200 and 400 mg. The incidence of leukopenia is 3.92% and agranulocytosis 0.21% in China, with about one third of reported cases of patients with agranulocytosis dying. Weight gain and clozapine-associated diabetes are also commonly reported in the Chinese population. Clozapine is currently the most commonly used treatment for schizophrenia in China. Chinese psychiatrists need to pay more attention to its potential toxic side effects when they make drug choices.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18203045     DOI: 10.1055/s-2007-993224

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  9 in total

1.  Clozapine: a distinct, poorly understood and under-used molecule.

Authors:  Ridha Joober; Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

Review 2.  More than 25 years of genetic studies of clozapine-induced agranulocytosis.

Authors:  S A J de With; S L Pulit; W G Staal; R S Kahn; R A Ophoff
Journal:  Pharmacogenomics J       Date:  2017-04-18       Impact factor: 3.550

3.  Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine.

Authors:  Xiaoping Yuan; Song Wang; Yudong Shi; Yating Yang; Yulong Zhang; Lei Xia; Kai Zhang; Huanzhong Liu
Journal:  Psychopharmacology (Berl)       Date:  2022-01-26       Impact factor: 4.530

4.  Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.

Authors:  D J Siskind; M Harris; A Phillipou; V A Morgan; A Waterreus; C Galletly; V J Carr; C Harvey; D Castle
Journal:  Epidemiol Psychiatr Sci       Date:  2016-07-18       Impact factor: 6.892

5.  Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study.

Authors:  Jianhua Chen; Ping Yang; Qian Zhang; Ruirui Chen; Peng Wang; Benxiu Liu; Wensheng Sun; Xuemin Jian; Siying Xiang; Juan Zhou; Ningning Li; Ke Wang; Chengwen Gao; Yanqin Wen; Chuanhong Wu; Jinmai Zhang; Yalin Zhao; Qiangzhen Yang; Meihang Li; Robert Stewart; Yuanchao Sun; Dun Pan; Yujuan Niu; Zhuo Wang; Yifeng Xu; Xingwang Li; Lin He; Zhiqiang Li; Yongyong Shi
Journal:  Transl Psychiatry       Date:  2021-06-03       Impact factor: 6.222

Review 6.  Clozapine for psychotic disorders in adults with intellectual disabilities.

Authors:  Muhammad Ayub; Khalid Saeed; Tariq A Munshi; Farooq Naeem
Journal:  Cochrane Database Syst Rev       Date:  2015-09-23

7.  Implementing a clozapine supply service in Australian community pharmacies: barriers and facilitators.

Authors:  Bethany Wilson; Sara S McMillan; Amanda J Wheeler
Journal:  J Pharm Policy Pract       Date:  2019-08-07

8.  Predictors of outcome in early onset schizophrenia: a 10-year follow-up study.

Authors:  Lingzi Xu; Yanqing Guo; Qingjiu Cao; Xue Li; Ting Mei; Zenghui Ma; Xinzhou Tang; Zhaozheng Ji; Liu Yang; Jing Liu
Journal:  BMC Psychiatry       Date:  2020-02-14       Impact factor: 3.630

9.  The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial.

Authors:  Francisco J Diaz; Richard C Josiassen; Jose de Leon
Journal:  J Clin Psychopharmacol       Date:  2018-10       Impact factor: 3.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.